驱动基因阳性的晚期肺腺癌精准治疗1例
| 作者: |
1张倩云,
1李鑫,
1杨邵瑜,
1陈雪琴
1 南京医科大学附属杭州医院(杭州市第一人民医院)肿瘤科，杭州 310006 |
| 通讯: |
陈雪琴
Email: chenlucy1437@aliyun.com |
| DOI: | 10.3978/j.issn.2095-6959.2019.11.048 |
摘要
现报告1例表皮生长因子受体(epidermal growth factor receptor，EGFR)基因19号外显子缺失突变阳性晚期肺腺癌病例的诊疗过程。患者入院后，根据其疾病分期以及基因突变情况，给予一线EGFR抑制剂吉非替尼治疗后部分缓解，进展后培美曲塞联合顺铂标准化疗也有部分缓解，很快再次进展，随后加入AURA17临床研究，奥希替尼治疗后部分缓解，4个月后复查进展，最后因多脏器功能衰竭死亡，总生存期约20个月。此病例的诊疗过程提示基因检测在晚期肺癌全程管理中的重要性。
关键词：
非小细胞肺癌；表皮生长因子受体；酪氨酸激酶抑制剂；靶向治疗
Precision treatment of advanced lung adenocarcinoma with driver gene positive: A case report
CorrespondingAuthor: CHEN Xueqin Email: chenlucy1437@aliyun.com
DOI: 10.3978/j.issn.2095-6959.2019.11.048
Abstract
The diagnosis and treatment of an advanced lung adenocarcinoma case with exon 19 deletion of EGFR gene positive is reported. First-line treatment with EGFR inhibitor gefitinib was administrated for the patient based on disease stage and genetic mutation state. After this treatment, the patient gained partially response. After 9.5 months, she progressed again and accepted standard chemotherapy, pemetrexed combined with cisplatin, which also showed partial response. But it soon made progress again. Fortunately, the patient could attend the AURA17 study, partial remission was achieved after treatment with osimertinib. Four months later, the patient's disease progressed. Finally, she died of multiple organ failure and overall survival was 20 months. The diagnosis and treatment of this case suggests the importance of genetic testing in the overall management of advanced lung cancer.
Keywords：
non-small cell lung cancer; epidermal growth factor receptor; tyrosine kinase inhibitors; targeted therapy